Actinium Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Actinium Pharmaceuticals's estimated annual revenue is currently $7.5M per year.
- Actinium Pharmaceuticals's estimated revenue per employee is $101,351
- Actinium Pharmaceuticals's total funding is $106.1M.
Employee Data
- Actinium Pharmaceuticals has 74 Employees.
- Actinium Pharmaceuticals grew their employee count by 19% last year.
Actinium Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and Chairman | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | VP, Head Radiation Sciences, Isotope Development and Supply Chain | Reveal Email/Phone |
4 | VP Clinical Development | Reveal Email/Phone |
5 | VP, Patent and Legal Counsel | Reveal Email/Phone |
6 | Head Human Resources | Reveal Email/Phone |
7 | Head Supplier Quality | Reveal Email/Phone |
8 | VP Clinical Development, BMT and Cellular Therapy | Reveal Email/Phone |
9 | Head Quality Control | Reveal Email/Phone |
10 | VP, Strategic Finance and Analysis | Reveal Email/Phone |
Actinium Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2M | 13 | 86% | N/A | N/A |
#2 | $1.1M | 7 | 75% | N/A | N/A |
#3 | $16.9M | 109 | 9% | N/A | N/A |
#4 | $42.6M | 275 | 10% | N/A | N/A |
#5 | $23.9M | 154 | 18% | N/A | N/A |
#6 | $9.5M | 61 | 74% | N/A | N/A |
#7 | $32.4M | 167 | -3% | $33.8M | N/A |
#8 | $0.9M | 6 | -45% | N/A | N/A |
#9 | $7.5M | 74 | 19% | $106.1M | N/A |
#10 | $18.8M | 121 | 27% | N/A | N/A |
What Is Actinium Pharmaceuticals?
Actinium Pharmaceuticals, Inc. is engaged in the development and commercialization of alpha particle immunotherapeutics based on its unique patent position for the utilization of actinium-225 and bismuth-213. It has facilities in Florham Park, New Jersey and Oak Ridge, Tennessee.
keywords:N/A
$106.1M
Total Funding
74
Number of Employees
$7.5M
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Actinium Pharmaceuticals News
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings...
Data Supports Actinium Pharmaceutical's research collaboration with AVEO Oncology to develop and advance a HER3 targeted radiotherapy to...
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and...
Other Companies in Sydney
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8M | 74 | 0% | N/A |
#2 | $13.7M | 74 | 6% | N/A |
#3 | $14M | 74 | -14% | N/A |
#4 | $18M | 74 | 10% | N/A |
#5 | $3.5M | 74 | 4% | N/A |